Uncategorized
Improvements seen with intravitreal infliximab for treatment of uveitis in Behçet’s disease
Intravitreal infliximab for the treatment of refractory posterior uveitis in Behçet’s disease significantly improved logMAR best corrected visual acuity and decreased central foveal thickness, according to a study.Researchers included 20 patients with refractory posterior uveitis in Behçet’s disease and assessed BCVA, vitreous haze, vasculitis, papillopathy and retinitis at baseline and postoperatively at day 1 and weeks 2, 4, 6, 8, 12 and 18. Additionally, flash electroretinogram and OCT were examined at baseline and postoperatively at weeks 4, 12 and 18.